Markets and Stocks January 2023 – Doc Holliday talks to Alan Green
Markets and Stocks January 2023 – Doc Holliday talks to Alan Green. We look at Doc’s new Twitter Spaces cast, before turning to stocks: 04:00 Avacta #AVCT | 06:00 Hvivo #HVO & Poolbeg Pharma #POLB | 08:15 – Longboat Energy #LBE / Energy stocks | 11:26 – Cadence Minerals #KDNC | 14:55 – Mining Companies | […]
New Vox Markets Podcast with our CEO Alan Green out now
New Vox Markets Podcast #podcast with our CEO Alan Green discussing: – Poolbegb Pharma #POLB – Amryt Pharma (Nasdaq: #AMYT) – Georgia Capital #CGEO – Marula Mining #MARU https://www.voxmarkets.co.uk/articles/alan-green-talks-about-poolbeg-pharma-georgia-capital-marula-mining-b8602ad/
Poolbeg Pharma #POLB – POLB 001 LPS human challenge clinical trial successfully completed & no serious adverse events reported.
12 December 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that, further to its announcement in July 2022, it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule […]
Poolbeg Pharma #POLB – Influenza Artificial Intelligence model build completed & on track to deliver outputs in Q2 2023
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that, further to its announcement in March 2022 , the construction of the computational artificial intelligence (AI) influenza disease model has been completed by CytoReason Limited (‘CytoReason’), indicating that it […]
Markets and Stocks – Doc Holliday talks to Alan Green
As we head towards Christmas, Alan Green and Doc Holliday talk markets and stocks. We discuss the macro events in the UK and the opportunities that Brexit and inflation could be throwing up for UK agriculture before we turn to stocks. Doc covers Harland & Wolff #HARL, ECR Minerals #ECR, Contango Holdings #CGO, Emmerson #EML, […]
Quoted Micro 21 November 2022
AQUIS STOCK EXCHANGE EDX Medical (EDX) completed its reversal into shell TECC Capital in a deal valued at £12m and £1.2m was raised at 6p a share. The share price returned from suspension and increased by 64.1% to 5.25p, but it is still below the placing price. EDX Medical develops digital diagnostic products and service […]
#POLB Poolbeg Pharma Plc- Capital Markets Day
17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a Capital Markets Day for analysts and institutional investors on Wednesday 30 November between 10am – 12:45pm. The event, which […]
Poolbeg Pharma #POLB – Poolbeg-led consortium awarded EUR 2.3m grant
15 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that ‘EncOVac’, a consortium led by Poolbeg Pharma, has been awarded €2.3m in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s […]
Quoted Micro 14 November 2022
AQUIS STOCK EXCHANGE First quarter trading at National Milk Records (NMRP) strengthened in all areas. Revenues increased by 4% to £5.98m. There was an 82% rise in genomic testing revenues to £151,000. Milk prices are expected to remain strong. The GenoCells services, which provide farmers with genomically driven individual animal cell count analysis, will be […]
Poolbeg Pharma #POLB – Artificial intelligence programme yields multiple novel RSV drug targets
8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with partner OneThree Biotech, Inc. through the discovery of novel drug targets for […]